|
Datasets with Lung_cancer |
The duplicated datasets indicate that this dataset include both pre-treatment and post-treatment samples, and partial analyses were conducted on each of the two timepoints. The dataset page shows more informations, and the analysis results of this dataset. |
Dataset | Source | Tissue | Cancer type level1 | Cancer type level2 | Drug type | Regimen | Timepoint |
GSE138267 | CDX | Tumor tissue | Lung cancer | Small cell lung cancer (SCLC) | Chemotherapy | NA | NA |
GSE207422_Sin | patients | Tumor tissue | Lung cancer | EGFR/ALK mutation negative non-small cell lung cancer (NSCLC) | Immunotherapy | sintilimab + carboplatin + (docetaxel or pemetrexed or emcitabine) | post |
GSE207422_Tor | patients | Tumor tissue | Lung cancer | EGFR/ALK mutation negative non-small cell lung cancer (NSCLC) | Immunotherapy | toripalimab + carboplatin + (docetaxel or pemetrexed or emcitabine) | post |
GSE139386 | H3122 cell line | Cell line | Lung cancer | EML4-ALK fusion-positive non-small cell lung cancer (NSCLC) | Targeted therapy | ceritinib | NA |
GSE149214 | PC9 cell line | Cell line | Lung cancer | EGFR-mutated non-small cell lung cancer (NSCLC) | Targeted therapy | erlotinib | NA |